CBT
IBB icon

Capital Bank & Trust’s iShares Biotechnology ETF IBB Stock Holding History

Capital Bank & Trust’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,540
Closed -$166K – 448
2020
Q1 		$166K Buy
+1,540
New +$177K ﹤0.01% 300

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Capital Bank & Trust's IBB Position: Q2 2020 in Review

Capital Bank & Trust sold out of iShares Biotechnology ETF (IBB) in Q2 2020, closing a stake of 1,540 shares — an estimated $166K sold.

Capital Bank & Trust first reported a position in IBB in Q1 2020 and held it in 1 quarter. The position peaked at $166K in Q1 2020. 766 funds tracked by Wall St. Rank hold IBB as of Q2 2020.

  • Capital Bank & Trust reported no remaining iShares Biotechnology ETF position as of Q2 2020 after selling out during the quarter.
  • Capital Bank & Trust sold 1,540 iShares Biotechnology ETF shares in Q2 2020, an estimated $166K.
  • Capital Bank & Trust first reported a position in iShares Biotechnology ETF in Q1 2020 and held it in 1 quarter.
  • Capital Bank & Trust's iShares Biotechnology ETF position peaked at $166K in Q1 2020.
  • 766 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.